Literature DB >> 22039784

History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents.

William C Campbell1.   

Abstract

The macrocyclic lactones enjoy a position of prominence in the control of parasites, and their history may be of interest, and even of use, in an age in which the search for chemotherapeutic agents has been transformed by modern technology. Much of their history has been recorded piecemeal in a wide variety of publications. The present review provides additional detail, and offers a personal perspective on the history of ivermectin and related avermectins. Brief notes are included on the subsequent development of other macrocyclic lactones. Milbemycin preceded the avermectins as a macrocyclic lactone of agricultural importance, but was used for a different purpose. Development of the avermectins arose from the isolation, in the laboratories of the Kitasato Institute, of a novel soil-dwelling bacterium and its transmittal (in 1974) to the laboratories of Merck & Co., Inc. There it was found (in 1975) to produce a potent anthelmintic substance, which was then identified and transmuted by interdisciplinary research into an antiparasitic product. Initially the focus was on its applicability to veterinary science and animal husbandry; and after developmental research by many scientific teams, the product was introduced commercially (in 1981) for the control of endoparasitic nematodes and ectoparasitic arthropods in livestock. Subsequently, special applications in human medicine were developed, and were successfully implemented in partnership with World Health Organization and several non-governmental organizations (NGOs).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22039784     DOI: 10.2174/138920112800399095

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  40 in total

1.  Subunit stoichiometry and arrangement in a heteromeric glutamate-gated chloride channel.

Authors:  Nurit Degani-Katzav; Revital Gortler; Lilach Gorodetzki; Yoav Paas
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-20       Impact factor: 11.205

Review 2.  Importance of microbial natural products and the need to revitalize their discovery.

Authors:  Arnold L Demain
Journal:  J Ind Microbiol Biotechnol       Date:  2013-08-30       Impact factor: 3.346

Review 3.  Glutamate-gated chloride channels.

Authors:  Adrian J Wolstenholme
Journal:  J Biol Chem       Date:  2012-10-04       Impact factor: 5.157

4.  The antihelminthic moxidectin enhances tonic GABA currents in rodent hippocampal pyramidal neurons.

Authors:  Jay Spampanato; Anne Gibson; F Edward Dudek
Journal:  J Neurophysiol       Date:  2018-01-24       Impact factor: 2.714

5.  Antiviral effect of theaflavins against caliciviruses.

Authors:  Mai Ohba; Tomoichiro Oka; Takayuki Ando; Saori Arahata; Asaka Ikegaya; Hirotaka Takagi; Naohisa Ogo; Chelsea Zhu; Kazuhiro Owada; Fumihiko Kawamori; Qiuhong Wang; Linda J Saif; Akira Asai
Journal:  J Antibiot (Tokyo)       Date:  2016-10-19       Impact factor: 2.649

Review 6.  Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer.

Authors:  Patrycja Nowak-Sliwinska; Leonardo Scapozza; Ariel Ruiz i Altaba
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-04-26       Impact factor: 10.680

Review 7.  Complementary Approaches with Free-living and Parasitic Nematodes to Understanding Anthelmintic Resistance.

Authors:  Janneke Wit; Clayton M Dilks; Erik C Andersen
Journal:  Trends Parasitol       Date:  2020-12-13

Review 8.  Heartworm disease - Overview, intervention, and industry perspective.

Authors:  Sandra Noack; John Harrington; Douglas S Carithers; Ronald Kaminsky; Paul M Selzer
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2021-04-27       Impact factor: 4.077

Review 9.  Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.

Authors:  Safaet Alam; Taslima Binte Kamal; Md Moklesur Rahman Sarker; Jin-Rong Zhou; S M Abdur Rahman; Isa Naina Mohamed
Journal:  Front Pharmacol       Date:  2021-06-14       Impact factor: 5.810

Review 10.  Development of emodepside as a possible adulticidal treatment for human onchocerciasis-The fruit of a successful industrial-academic collaboration.

Authors:  Jürgen Krücken; Lindy Holden-Dye; Jennifer Keiser; Roger K Prichard; Simon Townson; Benjamin L Makepeace; Marc P Hübner; Steffen R Hahnel; Ivan Scandale; Achim Harder; Daniel Kulke
Journal:  PLoS Pathog       Date:  2021-07-22       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.